\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationHelsinki (FI)
ProgrammesGaia-X is an initiative that develops, based on European values, a digital governance that can be applied to any existing cloud/ edge technology stack to obtain transparency, controllability, portability and interoperability across data and services. Gaia-X is not a market operator, nor will it operate directly or exclusively any of the services required by the governance.
The 5th Gaia-X Summit will showcase the latest achievements made by Gaia-X. Participants will have the opportunity to engage with industry leaders, experts, and innovators who are shaping the digital future. The event will feature inspiring keynotes, interactive workshops, and engaging panel discussions. Discover the latest insights, exchange ideas, and forge connections that will drive the next wave of digital transformation.
Further information on https://gaia-x.eu/summit-2024/
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
